Chronic myeloid leukemia in a patient with beta thalassemia major: A rare presentation
Document Type
Case Report
Department
Haematology/Oncology; Ophthalmology
Abstract
Chronic myeloid leukemia (CML) in patients with β-thalassemia major is a rare and concerning occurrence. The longer life expectancy of thalassemia patients, resulting from improved treatment options and better healthcare facilities, has led to the emergence of various health-related issues and complications. We present the case of a 24-year-old female diagnosed with β-thalassemia major at six months of age, who presented with weakness and lethargy in clinic. Investigations, including a bone marrow biopsy, confirmed CML in the chronic phase. Initial management with imatinib resulted in severe thrombocytopenia and failure to achieve a molecular response. The treatment was then switched to Ponatinib, leading to a favorable outcome with early molecular response. This case report highlights the increased risk of hematological malignancies in thalassemia patients and underscores the importance of vigilant monitoring in them. Furthermore, it emphasizes the role and effectiveness of third-generation tyrosine kinase inhibitors in the management of such cases.
Publication (Name of Journal)
Therapeutic Advances in Hematology
DOI
10.1177/20406207251353194
Recommended Citation
Hafeez, A.,
Shaikh, M.,
Mallick, A. H.,
Nathani, N.,
Alam, J.
(2025). Chronic myeloid leukemia in a patient with beta thalassemia major: A rare presentation. Therapeutic Advances in Hematology, 16.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_med_haematol_oncol/194
Comments
Issue and pagination are not provided by the author/publisher.